CN101605557B - 内切糖苷酶EndoS用于治疗免疫球蛋白G介导的疾病的用途 - Google Patents

内切糖苷酶EndoS用于治疗免疫球蛋白G介导的疾病的用途 Download PDF

Info

Publication number
CN101605557B
CN101605557B CN2007800512493A CN200780051249A CN101605557B CN 101605557 B CN101605557 B CN 101605557B CN 2007800512493 A CN2007800512493 A CN 2007800512493A CN 200780051249 A CN200780051249 A CN 200780051249A CN 101605557 B CN101605557 B CN 101605557B
Authority
CN
China
Prior art keywords
endos
igg
polypeptide
seq
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800512493A
Other languages
English (en)
Chinese (zh)
Other versions
CN101605557A (zh
Inventor
L·博乔克
马迪亚斯·科林
阿恩·奥尔森
R·霍默达
K·S·南达库玛
乌纳·莎侬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lufthansa Biopharmaceutical Co ltd
Original Assignee
Hansa Medical AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hansa Medical AB filed Critical Hansa Medical AB
Publication of CN101605557A publication Critical patent/CN101605557A/zh
Application granted granted Critical
Publication of CN101605557B publication Critical patent/CN101605557B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
CN2007800512493A 2006-12-13 2007-12-12 内切糖苷酶EndoS用于治疗免疫球蛋白G介导的疾病的用途 Expired - Fee Related CN101605557B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0624874.4 2006-12-13
GBGB0624874.4A GB0624874D0 (en) 2006-12-13 2006-12-13 Treatment
PCT/EP2007/010904 WO2008071418A2 (en) 2006-12-13 2007-12-12 Use of the endoglycosidase endos for treating immunoglobulin g mediated diseases

Publications (2)

Publication Number Publication Date
CN101605557A CN101605557A (zh) 2009-12-16
CN101605557B true CN101605557B (zh) 2013-08-28

Family

ID=37712062

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800512493A Expired - Fee Related CN101605557B (zh) 2006-12-13 2007-12-12 内切糖苷酶EndoS用于治疗免疫球蛋白G介导的疾病的用途

Country Status (9)

Country Link
US (1) US8889128B2 (cg-RX-API-DMAC7.html)
EP (1) EP2099477B1 (cg-RX-API-DMAC7.html)
JP (1) JP5414532B2 (cg-RX-API-DMAC7.html)
CN (1) CN101605557B (cg-RX-API-DMAC7.html)
AU (1) AU2007331736B2 (cg-RX-API-DMAC7.html)
CA (1) CA2671736C (cg-RX-API-DMAC7.html)
ES (1) ES2426352T3 (cg-RX-API-DMAC7.html)
GB (1) GB0624874D0 (cg-RX-API-DMAC7.html)
WO (1) WO2008071418A2 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2144681A4 (en) 2007-05-04 2011-10-05 Kurt G I Nilsson MATERIAL FOR THE DEPOSITION OF A BIOMOLECULAR
GB0821100D0 (en) * 2008-11-18 2008-12-24 Hansa Medical Ab Antibodies
EP2498812A4 (en) * 2009-11-13 2013-05-22 Bengt Guss IMMUNIZATION COMPOSITION FOR REDUCING STREPTOCOCCAL INFECTIONS
EP3135684B1 (en) 2010-05-26 2023-06-28 Intervacc AB Vaccine against streptococcal infections based on recombinant fusion proteins
GB201103780D0 (en) * 2011-03-04 2011-04-20 Hansa Medical Ab Treatment for ige-mediated disease
GB201115841D0 (en) * 2011-09-13 2011-10-26 Genovis Ab Protein and method
GB201201314D0 (en) * 2012-01-26 2012-03-07 Isis Innovation Composition
JP6282232B2 (ja) * 2012-02-10 2018-02-21 ユニバーシティー オブ メリーランド，ボルティモア 抗体及びそのＦｃフラグメントの酵素化学的糖鎖改変
TWI682033B (zh) * 2014-03-17 2020-01-11 泉盛生物科技股份有限公司 製造具有經修飾的糖苷化作用之重組糖蛋白之方法
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502305D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
EP3630968B8 (en) 2017-05-26 2024-07-03 Genovis AB Enzymes for glycan analysis
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
CN108623696B (zh) * 2018-04-20 2021-05-28 江南大学 一种利用纤维素固定化CBD-EndoS融合酶的方法
US20200165608A1 (en) * 2018-11-23 2020-05-28 Florida State University Research Foundation, Inc. Inhibition of vascular endothelial cell-mediated phagocytic processes for treatment of demyelinating conditions
GB202003129D0 (en) * 2020-03-04 2020-04-15 Hansa Biopharma AB Conditioning regimen for transplant of stem cells
GB202007434D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
US20230374542A1 (en) 2020-10-07 2023-11-23 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21)
CN113009130B (zh) * 2021-02-10 2022-08-23 中国医学科学院北京协和医院 一种用于诊断原发性干燥综合征的生物标志物及其用途
JP2024515626A (ja) 2021-04-16 2024-04-10 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン
EP4302770A1 (en) * 2022-07-08 2024-01-10 Hansa Biopharma AB Regimen for enzymatic desensitisation
EP4739775A1 (en) * 2023-07-07 2026-05-13 Emory University Recombinant glycosidases, pharmaceutical compositions, and uses in managing autoimmune or inflammatory conditions
CN119709701A (zh) * 2023-09-28 2025-03-28 上海糖岭生物医药有限责任公司 糖苷内切酶s2突变体、其制备方法及其在抗体糖基化改造中的应用
WO2025256977A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Novel igm and igg cleaving enzymes
WO2025256978A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Variants of igm and igg cleaving enzymes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
CN1756843B (zh) * 2003-03-04 2012-03-21 英特塞尔股份公司 化脓链球菌抗原
EP1807446A2 (en) * 2004-10-08 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Immunogenic and therapeutic compositions for streptococcus pyogenes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COLLIN M 等.EndoS, a novel secreted protein from Streptococcus pyogenes with endoglycosidase activity on human IgG.《EMSO JOURNAL》.2001,第20卷(第12期),3046-3055. *
COLLINM等.EndoS a novel secreted protein from Streptococcus pyogenes with endoglycosidase activity on human IgG.《EMSO JOURNAL》.2001

Also Published As

Publication number Publication date
AU2007331736B2 (en) 2013-04-04
JP2010512361A (ja) 2010-04-22
US8889128B2 (en) 2014-11-18
CA2671736A1 (en) 2008-06-19
CN101605557A (zh) 2009-12-16
GB0624874D0 (en) 2007-01-24
US20100135981A1 (en) 2010-06-03
WO2008071418A3 (en) 2008-09-04
WO2008071418A2 (en) 2008-06-19
ES2426352T3 (es) 2013-10-22
CA2671736C (en) 2017-01-10
EP2099477B1 (en) 2013-08-14
AU2007331736A1 (en) 2008-06-19
EP2099477A2 (en) 2009-09-16
JP5414532B2 (ja) 2014-02-12

Similar Documents

Publication Publication Date Title
EP2099477B1 (en) Use of the endoglycosidase EndoS for treating immunoglobulin G mediated diseases
JP5427409B2 (ja) 自己免疫疾患及び移植片拒絶反応を治療するためのＩｄｅＳプロテイナーゼ（化膿連鎖球菌由来）の使用
Gupta et al. Status of mannose-binding lectin (MBL) and complement system in COVID-19 patients and therapeutic applications of antiviral plant MBLs
JP3100005B2 (ja) ヒト免疫不全ウィルス感染・増殖抑制剤
Sgouras et al. Activity and functional importance of Helicobacter pylori virulence factors
JP6622591B2 (ja) ＴＮＦαポリペプチド阻害薬を発現する植物細胞の、治療法における使用
Koro et al. Carbamylation of immunoglobulin abrogates activation of the classical complement pathway
CN119161484A (zh) 抗asgr1单克隆抗体及其应用
CN116425888A (zh) 一种多肽tat-v2r1c及其应用
WO1998009981A9 (en) Human salivary proteins and fragments thereof having alpha-glucosidase inhibitory activity
CN101232900B (zh) IdeS蛋白酶(来自于酿脓链球菌)在自身免疫性疾病和移植排斥的治疗中的用途
US20220372111A1 (en) Polypeptide inhibitors of neutrophil elastase activity and uses thereof
US20210309984A1 (en) ChiA Enzyme
US20220241374A1 (en) Treatment of non-alcoholic steatohepatitis
TWI380995B (zh) 去糖基化長正五聚蛋白（ｐｅｎｔｒａｘｉｎ）ＰＴＸ３和去唾液酸化長正五聚蛋白ＰＴＸ３
JP2023533504A (ja) バイオフィルムの処置および予防のための併用療法
WO2003084998A1 (fr) Anticorps monoclonal neutralisant la megsine
WO2019134526A1 (zh) 膜型金属蛋白酶抑制蛋白和包含其的药物和药物组合物及各自的用途
Chen The role of C3 and alpha 2-macroglobulin in the activation of lectin pathway
MXPA98000891A (es) Mocarhagina, una proteasa del veneno de cobra y usos terapeuticos de la misma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: Lund, Sweden

Patentee after: Lufthansa biopharmaceutical Co.,Ltd.

Address before: Lund, Sweden

Patentee before: Hansa Medical AB

CP01 Change in the name or title of a patent holder
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130828

CF01 Termination of patent right due to non-payment of annual fee